DMD Care UK webinar for patients and families about vamorolone

21 March 2025

Following the approval of vamorolone as a Duchenne muscular dystrophy (DMD) treatment for use in NHS England and NHS Scotland, DMD Care UK has been working to help patients and their families, and clinicians, understand what this means for DMD treatment.

DMD Care UK hosted a webinar on 13 March to give information about vamorolone, and provide an opportunity for questions and answers with clinician experts and representatives from Duchenne UK, Muscular Dystrophy UK and Action Duchenne.

Watch the webinar:

DMD Care UK has also published a summary of available evidence on vamorolone.

Full guidelines for families on all corticosteroid treatment in DMD (covering prednisolone, deflazacort and vamorolone) will be available from DMD Care UK in April.

DMD Care UK is a collaborative initiative between the John Walton Muscular Dystrophy Research Centre at Newcastle University and Duchenne UK, embedded in the UK North Star Network. It is funded by Duchenne UK, The Duchenne Research Fund and Joining Jack.